一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Biochemical Reagents>Agonist Inhibitors>BMS-202
BMS-202
  • BMS-202

BMS-202 NEW

Price $102 $163 $323
Package 5mg 10mg 25mg
Supply Ability: 10g
Update Time: 2026-05-15

Product Details

Product Name: BMS-202 CAS No.: 1675203-84-5
Purity: 98.29% Supply Ability: 10g
Release date: 2026/05/15

Product Introduction

Bioactivity

NameBMS-202
DescriptionBMS-202 (PD1-PDL1 inhibitor 2) is a non-peptide PD-1/PD-L complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 with high affinity and blocks human PD-1/PD-L interactions, exhibiting antitumor activity.
Kinase AssayAll binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively).
In vitroMethods: HFB cell monolayers were treated with BMS-202 (0, 1, 2.5, 5 nM) for 24 hours, and scratch area measurements at 0h and 24h were compared. HFB monolayer cells were treated with BMS-202 (0, 1, 2.5, 5 nM) for 24 hours. After treatment, 0.5 μCi [3H]-proline was added, and incubation continued for 24 hours. Radioactive incorporation was then measured. Results: BMS-202 concentration-dependently inhibited HFB migration and collagen synthesis. [1] Methods: A375 melanoma cells were treated with BMS-202 (5 μM) or mitochondrial pyruvate carrier inhibitor GW604714X (10 μM) for 24 hours. Cell viability was assessed using the CCK-8 assay. Results: Combined treatment exhibited stronger cell viability suppression and apoptosis induction than either agent alone, indicating that mitochondrial dysfunction potentiates the antitumor effects of BMS-202. [2]
In vivoMethods: A375 cells were subcutaneously implanted into nude mice to establish a melanoma xenograft model. Once tumors became palpable, BMS-202 (20 mg/kg) was administered via intraperitoneal injection every 3 days. Mice were euthanized on the third day after the third injection. Results: Tumor growth was significantly slowed in the BMS-202-treated group, with a marked reduction in the proportion of Ki-67-positive cells in tumor tissue, confirming an antiproliferative effect in vivo. [2]
StorageStore at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility InformationDMSO : 45 mg/mL (107.27 mM), Sonication is recommended.
Ethanol : 83 mg/mL (197.85 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4.5 mg/mL (10.73 mM), Solution.
KeywordsThermal stabilization | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | nonpeptidic | Inhibitor | inhibit | immune-response | hydrophobic | dimeric | BMS-202 | BMS202 | BMS 202 | Apoptosis | antitumor | anti-proliferation
Inhibitors RelatedStavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate
Related Compound LibrariesApoptosis Compound Library | Bioactive Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | PPI Inhibitor Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$69.00
VIP4Y
TargetMol Chemicals Inc.
2026-05-11
VIP4Y
shandong perfect biotechnology co.ltd
2026-03-27
VIP2Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2026-05-20
$5.50
VIP7Y
Career Henan Chemical Co
2020-01-10

TargetMol Chemicals Inc.

6YR United StatesUnited States
  • Since: 2011-01-07
  • Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY
云阳县| 博野县| 门源| 石楼县| 安平县| 莲花县| 惠来县| 类乌齐县| 沛县| 衡南县| 靖安县| 南雄市| 民县| 通榆县| 邻水| 庆城县| 浦江县| 西峡县| 库尔勒市| 宝丰县| 探索| 会昌县| 澄迈县| 兰溪市| 宜昌市| 洪江市| 海原县| 黔东| 原阳县| 武鸣县| 阿勒泰市| 桐梓县| 大新县| 东山县| 铜鼓县| 沁水县| 宁南县| 衡阳市| 葫芦岛市| 甘肃省| 黄浦区|